Conference Day One - Wednesday, April 30, 2025
7:00 am Registration & Coffee
7:55 am Chair’s Opening Remarks
Upcoming Breakthroughs in GLP-1s: Combinations to Improve, Efficacy, Tolerability & Patient Experience
8:00 am Harnessing Biased Signaling to Enhance Incretin Pharmacodynamics
Synopsis
- Developing GLP-1 receptor agonists that preferentially activate pathways leading to enhanced glucose-dependent insulin secretion while minimizing pathways associated with adverse effects
- Approaches for accurately assessing incretin pharmacodynamics in humans
- Utilizing biased signaling to achieve personalized medicine
8:30 am Examining the Latest Advancements in GLP-1-Based Therapies: Combining GLP-1 & Amylin Analogues for Obesity & Diabetes Therapy
Synopsis
- Discussing the complementary physiological actions of GLP-1 and amylin in regulating glucose homeostasis, appetite, and satiety
- Highlighting how the combination of agonists can lead to enhanced glycemic control, weight loss, and improved cardiovascular outcomes compared to monotherapies.
- Explore potential challenges, such as the development of long-acting dual agonists with sustained efficacy and the need for further clinical trials to establish long-term safety and efficacy
9:00 am New Insulin Sensitizers as a Golden Combination With Glp-1 & Weight Loss Therapies
Synopsis
- Discussing novel oral insulin sensitizers targeting the mitochondrial pyruvate carrier to improve insulin sensitivity by shifting mitochondrial metabolism, increasing insulin response, and enhancing mitochondrial function
- Exploring insulin sensitizers beyond glycaemic control such as their potential to increase lean muscle mass and inflammation modulation
- Developing potent insulin-sensitising drugs that can be used in combination with GLP-1 receptor agonists to meet the large unmet need in the management of individuals with type 2 diabetes
9:30 am Preclinical Assessment of GLP-1 and Combination Therapies for Obesity: Insights from Mouse Models
Synopsis
- Assessment of Mono, Dual, and Tri-Agonist GLP-1 Therapies in Diet-Induced Obese and db/db Mouse Models
- Effects of GLP-1 Agonists on Weight Reduction and Body Composition in a Polygenic Mouse Model Under Ambient and Thermoneutral Conditions
- Imaging Approaches for Body Composition Assessment in Preclinical Models: Subcutaneous Fat, Visceral Adiposity, and Lean Mass
10:00 am Speed Networking
Synopsis
Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in the GLP-1 field. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and technique applications.
10:30 am Morning Break & Networking
Increasing Muscle Preservation During GLP-1 Treatment for Improved Metabolic Function
11:00 am Combining GLP-1s with Anti-myostatin Monoclonal Antibodies for Improved Muscle Mass Retention
Synopsis
- Adding anti-myostatin to semaglutide treatments to improve quality of weight loss
- Exploring combination therapies to promote the maintenance of weight loss post GLP-1 administration
- Exploring the use of myostatins for the preservation of muscle mass during and after treatment using GLP-1s
11:30 am Reserved for Perspectum – Expertise Partner
12:00 pm Considerations for Aging Users of GLP-1s Using Sarcopenia as a Case Study
Synopsis
- Discussing the potential impact of GLP-1 receptor agonists on sarcopenia in aging populations
- Exploring the complex interplay between GLP-1 signaling, muscle mass, and function
- Examining the potential for GLP-1s to contribute to muscle loss or, conversely, to have beneficial effects on muscle mass and function in older adults
12:30 pm MRI-based Body Composition Reimagined: Building a New Foundation for Treatment Differentiation Beyond Weight Loss
Synopsis
- FDA-cleared MRI-based body composition analysis provides a new standard for muscle and fat quantification enabling translation from population studies and clinical trials all the way into healthcare
- Studies on Personalized Fat and Muscle Z-score biomarkers show improved prediction of outcomes and that weight- and BMI-invariant treatment effects can be detected
- Understanding loss of muscle mass and shifts in fat distribution in the context of weight reduction and exploring the varying effects of liraglutide and tirzepatide in recent clinical trials
1:00 pm Lunch & Networking
2:00 pm Advancing ENDOSARM, An Oral, Novel Selective Adrogen Receptor Modulator (SARM), to Avoid Muscle and Augment Fat Loss When Combined with a GLP-1 RA for Potentially Higher Quality Weight Loss
Novel Clinical Development & Design Strategies for the Assessment of GLP-1s in Obesity Related Conditions
2:30 pm Overcoming Complex Pathophysiology & Patient Retention in Clinical Trials for GLP-1s to Treat MASH
Synopsis
- Discussing the benefits of placebo sharing strategies to overcome challenges in placebo arm requirements in clinical trials
- Outlining strategies for placebo patient retention when other GLP-1 trials are available
- Evaluating the use of real-world placebo patient databases to execute reliable time to event analysis
3:00 pm The Effects of GLP-1 Receptor Agonists on Lean Body Mass Loss & Associated Outcomes in Clinical Trials
Synopsis
- Navigating the rationale behind using GLP-1s to treat obesity, MASH and fatty liver disease
- Understanding the limitations of GLP-1 monotherapy and GLP-1/GIP dual agonists
- Strategies to increase the lean body mass retention of GLP-1 patients
3:30 pm DD01 – GLP-1/Glucagon Dual Agonist for the Treatment of MASH
Synopsis
- Developing a once weekly dual agonist of GLP-1 and glucagon receptors
- Exploring the benefits of half-life extension in obese/overweight patients with type 2 diabetes and MAFLD
- Assessing the benefits of DD01 in its ability to augment incretin therapy, acting through the glucagon receptor and enhancing liver lipolysis to treat the liver first
4:00 pm Panel: Delving into Clinical Trial Design to Accurately Assess GLP-1s in Comorbidities of Obesity
Synopsis
- Exploring strategies for patient selection and stratification using baseline characteristics and specific comorbidities to assess differential treatment effects
- Considering the ethical implications of placebo arms to obtain reliable clinical data whilst ensuring patients receive required care
- Drawing on real world data to ensure adequate sample size and statistical testing to detect clinically meaningful differences
4:30 pm Afternoon Refreshments & Poster Session
Synopsis
Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own developments in the GLP-1 Therapeutic world. Don’t miss out on the chance to submit your own posters and get ready to connect, learn, and present. To submit your poster please contact [email protected]
5:00 pm Roundtable Discussion: Subcutaneous Vs Oral Administration in GLP-1: Will Oral Administration Really Improve Patient Adherence?
Synopsis
- Examining the benefits and challenges of oral GLP-1 delivery, considering gastrointestinal degradation, first pass metabolism and formulation challenges
- Comparing the efficacy and safety profiles of glycaemic control in oral and subcutaneous GLP-1s
- Exploring real world evidence and data on patient adherence to injectables and oral medication – will the oral delivery make the side effects more bearable?
Forging Strategic Alliances Across Biotech, Pharma & Investors to Turbocharge Commercial & Scientific Breakthroughs in GLP-1 Development
5:30 pm Panel Discussion
Synopsis
- Hear from large pharma, investors, and experienced biotech leaders as they dive into the scientific and commercial factors of a setting up a successful partnership to develop GLP-1 based therapeutics for indications in obesity and beyond
- Uncover the key end-to-end key milestones that are evaluated when deciding on investment and partnership opportunities
- Ask your questions on what big pharma companies will be looking for next in their obesity and metabolism portfolios